These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28018881)

  • 1. Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study.
    Allen N; Walker SR; Liberti L; Sehgal C; Salek MS
    CMAJ Open; 2016; 4(4):E674-E678. PubMed ID: 28018881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Exploratory Analysis of Predictors of Concordance between Canadian Common Drug Review Reimbursement Recommendations and the Subsequent Decisions by Ontario, British Columbia and Alberta.
    Zoratti MJ; Xie F; Thorlund K; Allen N; Levine M
    Healthc Policy; 2020 Feb; 15(3):90-101. PubMed ID: 32176613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans.
    Salek S; Lussier Hoskyn S; Johns JR; Allen N; Sehgal C
    Front Pharmacol; 2019; 10():196. PubMed ID: 30983993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers.
    Foroutan N; Tarride JE; Xie F; Mills F; Levine M
    Pharmacoecon Open; 2019 Dec; 3(4):437-451. PubMed ID: 31041614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.
    McCormick JI; Berescu LD; Tadros N
    Orphanet J Rare Dis; 2018 Jan; 13(1):27. PubMed ID: 29382371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost shifting and timeliness of drug formulary decisions in atlantic Canada.
    Scobie AC; Mackinnon NJ
    Healthc Policy; 2010 Feb; 5(3):100-14. PubMed ID: 21286272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of drug coverage before and after the implementation of Canada's Common Drug Review.
    Gamble JM; Weir DL; Johnson JA; Eurich DT
    CMAJ; 2011 Nov; 183(17):E1259-66. PubMed ID: 22025648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
    Rawson NSB
    Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do Reimbursement Recommendations by the Canadian Agency for Drugs and Technology in Health Translate Into Coverage Decisions for Orphan Drugs in the Canadian Province of Ontario?
    Fontrier AM; Kanavos P
    Value Health; 2023 Jul; 26(7):1011-1021. PubMed ID: 36889379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada.
    Marshall DA; Willison DJ; Grootendorst P; LeLorier J; Maclure M; Kulin NA; Sheehy OE; Warren L; Sykora K; Rahme E
    Health Policy; 2007 Nov; 84(1):1-13. PubMed ID: 17570558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications.
    Salek SM; Lussier Hoskyn S; Johns J; Allen N; Sehgal C
    Front Pharmacol; 2018; 9():1578. PubMed ID: 30833899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using pharmacoeconomic analysis to make drug insurance coverage decisions.
    Anis AH; Rahman T; Schechter MT
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):119-26. PubMed ID: 10176146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditional Funding Recommendations for Drugs in Canada: A Cross-Sectional Analysis.
    Graili P
    Appl Health Econ Health Policy; 2023 Jul; 21(4):673-681. PubMed ID: 36609982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early-Stage Cannabis Regulatory Policy Planning Across Canada's Four Largest Provinces: A Descriptive Overview.
    Watson TM; Hyshka E; Bonato S; Rueda S
    Subst Use Misuse; 2019; 54(10):1691-1704. PubMed ID: 31076006
    [No Abstract]   [Full Text] [Related]  

  • 15. Inter-provincial variation in government drug formularies.
    Grégoire JP; MacNeil P; Skilton K; Moisan J; Menon D; Jacobs P; McKenzie E; Ferguson B
    Can J Public Health; 2001; 92(4):307-12. PubMed ID: 11962119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients' perspectives can be integrated in health technology assessments: an exploratory analysis of CADTH Common Drug Review.
    Berglas S; Jutai L; MacKean G; Weeks L
    Res Involv Engagem; 2016; 2():21. PubMed ID: 29062521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.
    Lexchin J
    BMJ Open; 2017 Oct; 7(10):e018372. PubMed ID: 29061631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of drug coverage in alberta before and after the introduction of the national common drug review process.
    Gamble JM; Eurich DT; Johnson JA
    Healthc Policy; 2010 Nov; 6(2):e117-44. PubMed ID: 22043227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic impact of delays in listing decisions by provincial drug plans after a positive Common Drug Review recommendation: the case of a smoking-cessation treatment.
    Paradis PE; Mishagina N; Carter V; Raymond V
    Healthc Q; 2012; 15(2):52-60. PubMed ID: 22688206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions.
    Spinner DS; Birt J; Walter JW; Bowman L; Mauskopf J; Drummond MF; Copley-Merriman C
    Clinicoecon Outcomes Res; 2013; 5():69-85. PubMed ID: 23403392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.